Inhibition of hydroxyapatite formation in the presence of titanocene–aminoacid complexes: an experimental and computational study

被引:0
作者
A. Chrissanthopoulos
N. Klouras
Ch. Ntala
D. Sevastos
E. Dalas
机构
[1] University of Patras,Department of Chemistry
[2] National and Kapodistrian University of Athens,Department of Chemistry
来源
Journal of Materials Science: Materials in Medicine | 2015年 / 26卷
关键词
Seed Crystal; DCPD; Titanocene; Cp2TiCl2; Octacalcium Phosphate;
D O I
暂无
中图分类号
学科分类号
摘要
Organometallic compounds have been used in various fields of chemistry, medicine and materials science. Central metal, stereochemical configuration and functional groups of the substitutes give to the organometallic compounds very special and selective properties. These properties have been used successfully in selective-antitumor-targeting, as well as anti-arthritic drugs. In the present investigation we study the influence of two organometallic compounds on the inhibition of crystallization of hydroxyapatite. These compounds are complexes of Ti(IV) with the general formula [Cp2Ti(aa)2]2+2Cl−, where Cp = η5-C5H5 cyclopentadienyl and aa the amino acid glycine or alanine. The experiments were conducted according to the constant composition technique in supersaturated solutions containing calcium and phosphate ions. The kinetic results indicate a surface diffusion controlled mechanism of the hydroxyapatite (HAP) crystals. The experiments prove that the presence of [Cp2Ti(Ala)2]2+2Cl− and [Cp2Ti(Gly)2]2+2Cl− complexes affects drastically the profile formation rate of the HAP crystals under biological conditions. The complex with the amino acid alanine provides a stronger inhibition of the formation rate comparing to the complex with glycine. The experimental observations are supported by computer calculations.
引用
收藏
相关论文
共 140 条
[1]  
Köpf H(1979)Titanocene dichloride—the first metallocene with cancerostatic activity Angew Chem Int Edn. 18 477-478
[2]  
Köpf-Maier P(2001)Enhanced anti-cancer activities of some derivatives of titanocene dichloride J Inorg Biochem 84 159-162
[3]  
Boyles JR(2000)Antitumour metallocenes: structure-activity studies and interactions with biomolecules Curr Med Chem 7 1289-1303
[4]  
Baird MC(2009)A proposed mechanism for the inhibitory effect of the anticancer agent titanocene dichloride on tumour gelatinases and other proteolytic enzymes J Biol Inorg Chem. 14 947-957
[5]  
Campling BG(2000)Complexes of gallium(III) and other metal ions and their potential in the treatment of neoplasia Exp Opin Invest Drugs. 9 1257-1270
[6]  
Jain N(2007)Antitumour bis(cyclopentadienyl) metal complexes: titanocene and molybdocene dichloride and derivatives Dalton Trans. 32 3474-3482
[7]  
Harding MM(1998)Water soluble, hydrolytically stable derivatives of the antitumor drug titanocene dichloride and binding studies with nucleotides J Organomet Chem 565 29-35
[8]  
Modski G(2008)Structure-activity studies of Ti(IV) complexes: aqueous stability and cytotoxic properties in colon cancer HT-29 cells J Biol Inorg Chem 13 685-692
[9]  
Pavlaki M(2008)Reconsideration of serum Ti(IV) transport: albumin and transferrin trafficking of Ti(IV) and its complexes J Am Chem Soc 130 2262-2270
[10]  
Debeli K(1987)Irritancy and anti-inflammatory activity of bis( Chem-Biol Interact. 61 277-291